Your CSV is on the way
We’ve sent your CSV file to email@email.com
Claimed by
owner Add to list
RedHill Biopharma
Former names:
Proprietary Drugs for Gastrointestinal and Infectious Diseases
Stealth Mode
PUBLIC on NASDAQ on Jan, 2012
RedHill Biopharma
RedHill Biopharma Overview
Cumulative Funding Raised Over Time ($)
Employees Over Time
RedHill Biopharma Climate Tech relevance
undefined
No Data, yet.
Sorry, no content found under this section.
Jun 2, 2026
finance.yahoo.com
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
null
Apr 30, 2026
finance.yahoo.com
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
null
Apr 30, 2026
www.prnewswire.com
RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-1042, designed for enhanced tolerability, safety profile and patient adherence, that...
null
Apr 27, 2026
finance.yahoo.com
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
null
Apr 27, 2026
www.prnewswire.com
2025 was a year of tenacity, strategic transactions and building traction for RedHill Talicia® business transformed: Formation of Talicia Holdings Inc. (THI)...
null
Apr 22, 2026
www.prnewswire.com
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
null
Apr 22, 2026
www.prnewswire.com
New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects...
null
Feb 25, 2026
finance.yahoo.com
Joint U.S. Commercialization of RedHill's Talicia® Commences
#Partners #Investment
Feb 25, 2026
finance.yahoo.com
CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®
#Product Stage #Partners #FDA approved/pending approval
Feb 25, 2026
www.prnewswire.com
The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity...
#Partners #Investment #Product Stage
Jan 5, 2026
finance.yahoo.com
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
#Product Stage #FDA approved/pending approval
Dec 15, 2025
finance.yahoo.com
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
#Product Stage #Partners
Dec 1, 2025
finance.yahoo.com
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
#Partners #Product Stage
Dec 1, 2025
www.prnewswire.com
/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on November 26,...
null
Nov 4, 2025
finance.yahoo.com
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
#Product Stage #Partners
Nov 4, 2025
www.prnewswire.com
/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York...
undefined
Oct 22, 2025
finance.yahoo.com
RedHill Biopharma Receives Nasdaq Staff Determination Notification
undefined
Oct 22, 2025
www.prnewswire.com
On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the...
#Partners
Oct 20, 2025
finance.yahoo.com
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
#Partners #Investment
Oct 20, 2025
www.prnewswire.com
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S....
#Partners #Investment #Customers
Oct 20, 2025
finance.yahoo.com
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
#Partners #Investment #Customers
Oct 6, 2025
finance.yahoo.com
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
#Partners
Oct 6, 2025
www.prnewswire.com
The deal aims to accelerate Talicia's entry into new Middle East markets Under the terms of the agreement RedHill will receive $500,000 in guaranteed payments,...
#Product Stage #Customers #Partners
Sep 29, 2025
www.prnewswire.com
The New York Supreme Court has, on appeal, upheld its original summary judgment ruling in favor of RedHill The New York Supreme Court unequivocally dismissed...
undefined
Sep 29, 2025
finance.yahoo.com
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo
undefined
Sep 5, 2025
finance.yahoo.com
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights
#Product Stage #Customers #Partners #Investment
Aug 20, 2025
finance.yahoo.com
RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win
undefined
Aug 20, 2025
www.prnewswire.com
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York...
undefined
Aug 18, 2025
finance.yahoo.com
RedHill Received Talicia® Licensing Payments Totaling $1.1 Million
#Customers #FDA approved/pending approval
Aug 18, 2025
www.prnewswire.com
RedHill has received its first Talicia sales milestone payment as well as royalties and other payments, totaling $1.1 million, following the first ex-U.S....
#Customers #FDA approved #Partners
Jul 21, 2025
www.prnewswire.com
The positive FDA feedback allows for: A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium...
#Product Stage #Partners
Jul 21, 2025
finance.yahoo.com
RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease
#Product Stage #Partners
Jul 1, 2025
finance.yahoo.com
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
undefined
Jul 1, 2025
finance.yahoo.com
RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer
#Product Stage
Jul 1, 2025
www.prnewswire.com
Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer...
#Product Stage #Partners
May 13, 2025
finance.yahoo.com
RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win
#Product Stage #Partners
May 2, 2025
finance.yahoo.com
RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress
undefined
Apr 28, 2025
finance.yahoo.com
RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107
#Product Stage #FDA approved/pending approval
Apr 28, 2025
www.prnewswire.com
Strong Use of Composition-of-Matter Coverage: Patent protects the molecular structure of RHB-107, providing market exclusivity beyond method-of-use claims...
#Product Stage #FDA approved/pending approval
Apr 17, 2025
finance.yahoo.com
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
#Public Trading
Apr 16, 2025
finance.yahoo.com
RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption
#Product Stage #FDA approved/pending approval
Apr 10, 2025
finance.yahoo.com
RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights
#Product Stage #Partners #Customers #Investment
Mar 31, 2025
uk.finance.yahoo.com
Surrey loses rush-hour taxis to thousands of school runs
#Customers #Partners
Mar 18, 2025
finance.yahoo.com
RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation
#Product Stage #Partners
Mar 18, 2025
www.prnewswire.com
RedHill plans to submit UK MAA1 for Talicia for H. pylori infection, using MHRA's2 new fast-track approval process, referencing FDA approval, with potential UK...
undefined
Mar 12, 2025
www.prnewswire.com
The planned innovative Phase 2 study of RHB-2041 will be the first ever clinical study in Crohn's Disease (CD) patients who are all MAP-positive, and will...
undefined
Mar 12, 2025
finance.yahoo.com
RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results
#Product Stage
Feb 27, 2025
www.prnewswire.com
Guy Goldberg, RedHill's Chief Business Officer, presents today a business update at the European Life Sciences CEO Forum The update covers: The recent...
#Product Stage #Partners #Customers #FDA approved/pending approval
Feb 27, 2025
finance.yahoo.com
RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum
#Product Stage #Partners #Customers
Feb 26, 2025
www.pharmaceutical-technology.com
RedHill and Hyloris sign agreement for Bekinda’s development
#Partners #Product Stage
Feb 25, 2025
www.prnewswire.com
- Hyloris will pay RedHill an upfront payment and up to $60 million in potential milestone payments, plus up to mid-20s percent royalties on revenues, in...
#Partners
Feb 25, 2025
finance.yahoo.com
RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties
#Partners
Feb 5, 2025
www.clinicaltrialsarena.com
RedHill Biopharma launches trial of combination therapy for prostate cancer
#Product Stage
Feb 4, 2025
finance.yahoo.com
RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer
#Product Stage #Partners
Feb 4, 2025
www.prnewswire.com
The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with...
#Product Stage #Partners #Investment
Feb 4, 2025
www.prnewswire.com
The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with...
#Product Stage #Partners #Investment
Jan 21, 2025
finance.yahoo.com
RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published
#Customers
Dec 10, 2024
finance.yahoo.com
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
#Partners
Dec 3, 2024
finance.yahoo.com
RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court
#Partners
Dec 2, 2024
finance.yahoo.com
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
undefined
Dec 2, 2024
www.prnewswire.com
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company has...
undefined
Oct 28, 2024
finance.yahoo.com
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
undefined
Oct 23, 2024
finance.yahoo.com
RedHill Biopharma and Duke Collaborate on Opaganib Development
#Partners
Oct 22, 2024
www.prnewswire.com
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
#Partners
Oct 14, 2024
www.prnewswire.com
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
#Partners
Oct 1, 2024
www.prnewswire.com
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
#Customers #Partners
Oct 1, 2024
finance.yahoo.com
RedHill Biopharma Secures Opaganib COVID-19 Patent
undefined
Sep 30, 2024
www.prnewswire.com
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
#Customers #Partners
Sep 9, 2024
www.prnewswire.com
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines
#Customers
Sep 5, 2024
www.prnewswire.com
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received...
#Public Trading
Sep 5, 2024
www.prnewswire.com
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
#Public Trading
Sep 3, 2024
www.prnewswire.com
New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality
#Customers #Partners
Aug 29, 2024
www.prnewswire.com
RedHill Biopharma Announces First Half 2024 Business Highlights
#Customers #Partners #Investment #Layoffs
Aug 29, 2024
www.prnewswire.com
A transformed RedHill: Numerous potential catalysts Strengthened cash balance and control over our destiny following the Termination Agreement with Movantik...
#Customers #Partners #Investment #Layoffs
Aug 26, 2024
www.prnewswire.com
RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma
#Customers #Partners
Aug 21, 2024
www.prnewswire.com
Talicia® Launched in the United Arab Emirates
#Customers #Expand
Aug 21, 2024
finance.yahoo.com
Three Undiscovered Gems in the United States Market
#Investment, Public Trading
Aug 19, 2024
finance.yahoo.com
Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested
#Public Trading
Aug 19, 2024
www.prnewswire.com
RedHill Announces Positive Obesity and Diabetes Results with Opaganib
#Investment #Partners
Aug 16, 2024
www.prnewswire.com
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
#Public Trading #Management Changes
Aug 1, 2024
www.prnewswire.com
Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease
#Investment, Expand
Jul 22, 2024
www.prnewswire.com
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien
#Partners
Jul 9, 2024
www.prnewswire.com
RedHill Biopharma Terminates License Agreement for Aemcolo®
#Partners
Jun 3, 2024
www.prnewswire.com
RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
#Investment
May 22, 2024
uk.finance.yahoo.com
Pensioners win £9,000 back in 16-year council tax battle
#Customers
May 6, 2024
www.prnewswire.com
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
#Investment
Apr 24, 2024
www.prnewswire.com
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
#Investment #Partners
Apr 10, 2024
finance.yahoo.com
RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)
#Public Trading
Apr 8, 2024
www.prnewswire.com
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
#Investment #Expand
Apr 2, 2024
www.prnewswire.com
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
#Investment
Mar 11, 2024
www.prnewswire.com
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
#Investment
Mar 5, 2024
www.prnewswire.com
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
#Partners
Feb 20, 2024
www.prnewswire.com
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
#Investment #Partners
Jan 26, 2024
www.prnewswire.com
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
#Investment
Jan 25, 2024
www.prnewswire.com
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
#Customers
Jan 25, 2024
www.prnewswire.com
RedHill Biopharma Announces $8 Million Registered Direct Offering
#Investment
Dec 20, 2023
www.prnewswire.com
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
#Investment
Dec 12, 2023
www.prnewswire.com
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
#Public Trading
Dec 4, 2023
www.prnewswire.com
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
#Investment
Dec 4, 2023
www.prnewswire.com
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
#Investment
Nov 27, 2023
www.prnewswire.com
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
#Investment
Nov 14, 2023
www.prnewswire.com
RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market
#Public Trading
Oct 3, 2023
www.prnewswire.com
RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study
#Investment
Sep 22, 2023
www.prnewswire.com
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
#Public Trading
Sep 18, 2023
www.prnewswire.com
RedHill Announces FDA sNDA Approval for Talicia®
#Customers #Partners
Sep 5, 2023
www.prnewswire.com
RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)
#Investment
Aug 17, 2023
www.prnewswire.com
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
#Investment #Management Changes
Aug 1, 2023
www.prnewswire.com
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.
#Partners #Expand
Jul 31, 2023
www.prnewswire.com
RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
#Investment #Partners
Jul 25, 2023
www.prnewswire.com
RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise
#Investment
Jul 21, 2023
www.prnewswire.com
RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development
#Investment #Partners
Jul 21, 2023
www.prnewswire.com
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds
#Investment
Jun 12, 2023
www.prnewswire.com
RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights
#Investment #Management Changes
May 22, 2023
www.prnewswire.com
RedHill Provides R&D Update
#Management Changes
May 15, 2023
www.prnewswire.com
RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
#Public Trading
May 9, 2023
www.prnewswire.com
RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week
#Customers
May 1, 2023
www.prnewswire.com
RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting
#Partners
Apr 28, 2023
www.prnewswire.com
RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights
#Investment, Expand
Apr 17, 2023
finance.yahoo.com
Benign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% Plummet
#Customers
Apr 11, 2023
www.prnewswire.com
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
#Public Trading
Apr 3, 2023
www.prnewswire.com
RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering
#Investment
Mar 30, 2023
www.prnewswire.com
RedHill Biopharma Announces $6 Million Registered Direct Offering
#Investment
Mar 23, 2023
finance.yahoo.com
RedHill Biopharma Ltd.'s (NASDAQ:RDHL) market cap dropped US$146m last week; Individual investors bore the brunt
#Customers #Investment
Mar 21, 2023
www.prnewswire.com
RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders
#Customers
Mar 16, 2023
www.prnewswire.com
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
#Public Trading #Management Changes
Mar 9, 2023
www.prnewswire.com
RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor
#Investment
Feb 28, 2023
finance.yahoo.com
RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development
#Partners
Feb 28, 2023
www.prnewswire.com
RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program
#Partners
Feb 16, 2023
finance.yahoo.com
RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
#Investment #Expand
Feb 16, 2023
www.prnewswire.com
RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support
#Customers #Expand
Feb 15, 2023
www.prnewswire.com
RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome
#Partners
Feb 10, 2023
finance.yahoo.com
Raleigh pharma sheds debt in exchange for top-selling drug. Now what?
null
Oct 26, 2022
www.prnewswire.com
RedHill Presents New Talicia® and Movantik® Data Analyses at ACG 2022
#Customers, Investment
May 9, 2022
www.prnewswire.com
RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor
#Investment
Apr 11, 2022
www.benzinga.com
RedHill Biopharma Says Opaganib Can Potentially Work Against COVID-19 Omicron Subvariants - Redhill Biopharma (NASDAQ:RDHL)
#Customers
Mar 1, 2022
www.eurekalert.org
RedHill announces positive phase 2 study results with oral RHB-107 in non-hospitalized COVID-19
#Investment
Jan 6, 2022
www.prnewswire.com
RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates
#Partners #Investment
Nov 18, 2021
www.prnewswire.com
RedHill Biopharma Announces Underwritten Public Offering of American Depositary Shares
#Public Trading #Investment
Sep 14, 2021
www.prnewswire.com
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients
#Customers
Feb 28, 2021
www.calcalistech.com
Israel's RedHill Biopharma testing oral pill that cures Covid-19 symptoms
#Customers, Public Trading
Dec 15, 2020
www.prnewswire.com
RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model
#Investment #Expand
Dec 2, 2020
www.usnews.com
Coronavirus Pandemic Boosting Anti-Virus Research Around the World
null
Nov 26, 2020
www.pharmanewsdaily.com
RedHill Biopharma expands manufacturing capacity of Covid-19 drug candidate opaganib in US - www.PharmaNewsDaily.com
#Partners #Expand
Oct 14, 2020
www.calcalistech.com
Israel's Redhill Biopharma signs manufacturing deal for potential Covid-19 treatment
#Partners #Expand
Oct 14, 2020
www.globenewswire.com
RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections
#Investment #Expand
Oct 8, 2020
www.globenewswire.com
RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca
#Partners #Expand
Oct 7, 2020
www.globenewswire.com
RedHill Biopharma's Opaganib COVID-19 Study Passes Second Independent Committee Review
#Investment
Sep 22, 2020
www.globenewswire.com
Brazil Approves RedHill Biopharma's Phase 2/3 COVID-19 Study with Opaganib
#Investment, Expand
Sep 8, 2020
www.globenewswire.com
RedHill Biopharma's Opaganib Demonstrates Complete Inhibition of SARS-CoV-2
#Investment #Expand
Sep 3, 2020
www.globenewswire.com
RedHill Biopharma's Opaganib Awarded COVID-19 Grant by State of Pennsylvania
#Investment #Partners #Expand
Aug 27, 2020
www.globenewswire.com
RedHill Biopharma Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
#Investment, Expand
Aug 13, 2020
www.globenewswire.com
RedHill Biopharma and Cosmo Pharmaceuticals to Expand Strategic Partnership with Exclusive Licensing Agreement and Manufacturing Agreement for Multiple Products
#Partners #Investment
Aug 11, 2020
www.globenewswire.com
RedHill Biopharma's Phase 2/3 COVID-19 Study Approved in Mexico
#Investment, Expand
Aug 3, 2020
www.globenewswire.com
RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik®
#Acquisition #Partners
Jul 31, 2020
www.globenewswire.com
RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
#Investment
Jul 30, 2020
www.globenewswire.com
RedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19
#Investment, Expand
Jul 28, 2020
www.globenewswire.com
RedHill Biopharma Publishes Positive IBS-D Phase 2 Study Data in The American Journal of Gastroenterology
#Investment #Expand
Jul 22, 2020
www.globenewswire.com
RedHill Biopharma Accelerates Phase 2/3 COVID-19 Program with Addition of Brazil and Mexico
#Customers, Expand
Jul 16, 2020
www.globenewswire.com
RedHill Biopharma Receives Approval for Phase 2/3 COVID-19 Study in Russia
#Investment #Expand
Jun 29, 2020
www.globenewswire.com
RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK
#Customers #Expand
Jun 24, 2020
www.globenewswire.com
Publication of Data from Severe COVID-19 Patients Shows Substantial Benefit to Patients Treated with RedHill's Opaganib Compared to Matched Case-Control Group
#Investment #Expand
Jun 18, 2020
www.globenewswire.com
RedHill Biopharma Expands Opaganib COVID-19 Phase 2/3 Study with Clinical Trial Applications in Italy and UK
#Investment, Customers
Jun 10, 2020
www.globenewswire.com
RedHill Biopharma Submits COVID-19 Clinical Trial Application for Phase 2/3 Study with Opaganib
#Investment #Expand
Jun 8, 2020
www.globenewswire.com
RedHill Biopharma to Provide Update on its COVID-19 and other Development Programs at MedInvest Virtual Infectious Diseases and Immunology Conference
#Management Changes
May 8, 2020
www.globenewswire.com
RedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S.
#Investment #Expand
May 5, 2020
www.globenewswire.com
RedHill Biopharma Announces Publication of Talicia® Pivotal Phase 3 Study Results in Annals of Internal Medicine
#Customers, Expand
Apr 20, 2020
www.globenewswire.com
RedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19
#Partners
Apr 13, 2020
www.globenewswire.com
RedHill Biopharma Provides Initial Update from its Opaganib COVID-19 Compassionate Use Program in Israel
#Customers #Partners #Expand
Apr 7, 2020
www.timesofisrael.com
Israel's Redhill Biopharma gets green light for experimental COVID-19 treatment
null
Mar 15, 2020
www.israel21c.org
Israeli pharma company launches drug for H. pylori in US market
#Customers #Expand
Mar 11, 2020
www.globenewswire.com
RedHill Biopharma Provides Update on Opaganib (Yeliva®)
#Investment #Expand
Feb 25, 2020
www.globenewswire.com
RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners
#Investment #Acquisition #Partners
Feb 25, 2020
en.globes.co.il
RedHill buys AstraZeneca constipation drug rights
#Acquisition #Investment
Jan 27, 2020
www.globenewswire.com
RedHill Biopharma Launches H. pylori Disease State Awareness Field Campaign Ahead of Talicia® Launch
#Customers #Expand
Jan 21, 2020
www.globenewswire.com
RedHill Biopharma to Focus Commercial Efforts on Talicia® and Aemcolo®;Discontinuing Promotion of Legacy Products
#Partners
Jan 2, 2020
www.globenewswire.com
RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106
#Partners
Dec 17, 2019
www.globenewswire.com
RedHill Biopharma Initiates U.S. Promotion of Aemcolo® for Travelers' Diarrhea
#Customers #Partners #Investment #Expand
Nov 15, 2019
www.globenewswire.com
Dual-Listed RedHill Biopharma to Voluntarily Delist from Tel-Aviv Stock Exchange
#Public Trading
Nov 12, 2019
www.globenewswire.com
RedHill Biopharma Announces Publication of RHB-102 Gastroenteritis Phase 3 Study Results in JAMA
#Investment #Expand
Nov 5, 2019
www.calcalistech.com
RedHill Receives FDA Approval for H. Pylori Gastric Drug
null
Oct 18, 2019
www.globenewswire.com
RedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers' Diarrhea Drug AEMCOLO
#Investment #Partners
Oct 11, 2019
www.globenewswire.com
RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn's Disease
#Investment
Aug 21, 2019
www.globenewswire.com
RedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn's Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting
#Investment #Expand
Jul 3, 2019
www.globenewswire.com
RedHill Biopharma Announces FDA Acceptance of New Drug Application for Talicia®
#Investment #Customers
Jun 10, 2019
www.globenewswire.com
RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn's Disease and RHB-204 for NTM Infections
#Investment, Expand
May 28, 2019
www.globenewswire.com
RedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer
#Management Changes #Expand
May 21, 2019
www.globenewswire.com
RedHill Biopharma Expands Commercial Management Team Ahead of Planned Talicia® Launch
#Management Changes #Expand
May 7, 2019
www.globenewswire.com
RedHill Biopharma Submits New Drug Application for Talicia® for H. pylori Infection
#Investment #Expand
Mar 4, 2019
www.globenewswire.com
RedHill Biopharma Announces New European and Japanese Patents for Talicia®
#Investment
Jan 17, 2019
globenewswire.com
RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA® for H. pylori Infection
#Investment
Dec 9, 2018
en.globes.co.il
RedHill Biopharma raises $20m on Nasdaq
#Investment
Dec 3, 2018
www.timesofisrael.com
Israel's RedHill says drug shown effective in eradicating gut infection
null
Jul 30, 2018
www.timesofisrael.com
RedHill's drug for Crohn's disease shows positive results - study
null
Jul 24, 2018
www.calcalistech.com
Gastro Treatment Company RedHill Wants to Raise $117 on Nasdaq
#Investment #Public Trading
Nov 17, 2017
seekingalpha.com
RedHill Biopharma: When Good News Means Nothing (NASDAQ:RDHL)
#Management Changes #Layoffs
Nov 13, 2017
globenewswire.com
RedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares
#Investment #Public Trading
Apr 10, 2017
www.marketwired.com
http://www.marketwired.com/press-release/intelgenx-redhill-biopharma-announce-marketing-approval-rizaportr-migraines-luxembourg-otcqx-igxt-2209596.htm
#N/A
Dec 22, 2016
www.globes.co.il
RedHill BioPharma raises $38m in Nasdaq offering
#Investment #Public Trading
Jul 22, 2016
globenewswire.com
RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead of Confirmatory Phase III Study for H. pylori Infection
#N/A
Jul 19, 2015
www.globes.co.il
RedHill BioPharma raises $40 million on Nasdaq
#Investment #Public Trading
Jun 15, 2015
www.globes.co.il
RedHill Biopharma soars on Phase III trial results
#Investment
Feb 11, 2015
www.globes.co.il
RedHill Biopharma raises $12.5m on Nasdaq
#Investment
Dec 18, 2014
www.globes.co.il
RedHill boosted by University of Minnesota deal
#Acquisition #Partners
Jan 22, 2014
www.globes.co.il
RedHill Biopharma raises $11.7m in private placement
#Investment
Similar Companies
Driven by Finder AI
Related Content
Lists. Maps. Reports
Team Members
undefined
Contact Team
Affiliated Organizations
(undefined)Web & social links
https://www.redhillbio.com/home/default.aspx
Locations
Israel
Offices Abroad
Photos & videos
(0)No Data, yet.
Sorry, no content found under this section.
RedHill Biopharma Financials
Cumulative Funding Raised Over Time ($)
No Data, yet.
Sorry, no content found under this section.
Public Offerings & Exits
Private Equity Funding
Non-Equity Funding
Mergers and Acquisitions
RedHill Biopharma Lifecycle
Cumulative Funding Raised Over Time ($)
Timeline
Employees Over Time
News Over Time
No Data, yet.
Sorry, no content found under this section.
RedHill Biopharma News
News Over Time
No Data, yet.
Sorry, no content found under this section.
News Articles
Jun 2, 2026
finance.yahoo.com
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
null
Apr 30, 2026
finance.yahoo.com
RedHill's RHB-204 Demonstrates Comparable MAP Killing Efficacy to RHB-104 - Important Step in RHB-204 Development for MAP-related Crohn's Disease
null
Apr 30, 2026
www.prnewswire.com
RHB-2041 is a next-generation optimized formulation of RedHill's oral RHB-1042, designed for enhanced tolerability, safety profile and patient adherence, that...
null
Apr 27, 2026
finance.yahoo.com
RedHill Biopharma Announces Full-Year 2025 Financial Results and Operational Highlights
null
Apr 27, 2026
www.prnewswire.com
2025 was a year of tenacity, strategic transactions and building traction for RedHill Talicia® business transformed: Formation of Talicia Holdings Inc. (THI)...
null
Apr 22, 2026
www.prnewswire.com
RedHill's Opaganib Enhances Efficacy of Neuroblastoma Chemo Combination and Augment Anti-Tumor Immunity in Triple-Negative Breast Cancer in Preclinical Studies - New Data Presented at AACR 2026
null
Apr 22, 2026
www.prnewswire.com
New preclinical data, independently presented in two posters at the 2026 American Association for Cancer Research (AACR) Annual Meeting, show positive effects...
null
Feb 25, 2026
finance.yahoo.com
Joint U.S. Commercialization of RedHill's Talicia® Commences
#Partners #Investment
Feb 25, 2026
finance.yahoo.com
CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®
#Product Stage #Partners #FDA approved/pending approval
Feb 25, 2026
www.prnewswire.com
The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity...
#Partners #Investment #Product Stage
Jan 5, 2026
finance.yahoo.com
RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects
#Product Stage #FDA approved/pending approval
Dec 15, 2025
finance.yahoo.com
RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells
#Product Stage #Partners
Dec 1, 2025
finance.yahoo.com
RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement
#Partners #Product Stage
Dec 1, 2025
www.prnewswire.com
/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on November 26,...
null
Nov 4, 2025
finance.yahoo.com
RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement
#Product Stage #Partners
Nov 4, 2025
www.prnewswire.com
/PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York...
undefined
Oct 22, 2025
finance.yahoo.com
RedHill Biopharma Receives Nasdaq Staff Determination Notification
undefined
Oct 22, 2025
www.prnewswire.com
On October 16, 2025, the Company received a Staff Determination notification from The Nasdaq Stock Market LLC regarding continued non-compliance with the...
#Partners
Oct 20, 2025
finance.yahoo.com
RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal
#Partners #Investment
Oct 20, 2025
www.prnewswire.com
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S....
#Partners #Investment #Customers
Oct 20, 2025
finance.yahoo.com
CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO
#Partners #Investment #Customers
Oct 6, 2025
finance.yahoo.com
RedHill Biopharma Signs New $1.8 Million Plus Sales Royalties Middle East Deal For Talicia®
#Partners
Oct 6, 2025
www.prnewswire.com
The deal aims to accelerate Talicia's entry into new Middle East markets Under the terms of the agreement RedHill will receive $500,000 in guaranteed payments,...
#Product Stage #Customers #Partners
Sep 29, 2025
www.prnewswire.com
The New York Supreme Court has, on appeal, upheld its original summary judgment ruling in favor of RedHill The New York Supreme Court unequivocally dismissed...
undefined
Sep 29, 2025
finance.yahoo.com
RedHill Wins New York Supreme Court Appeal, Upholding $10 Million Summary Judgment Against Kukbo
undefined
Sep 5, 2025
finance.yahoo.com
RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights
#Product Stage #Customers #Partners #Investment
Aug 20, 2025
finance.yahoo.com
RedHill Biopharma Awarded $1.8 Million in Legal Costs and Expenses by New York Supreme Court in Addition to its Prior $8.25 Million Summary Judgment Win
undefined
Aug 20, 2025
www.prnewswire.com
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the New York...
undefined
Aug 18, 2025
finance.yahoo.com
RedHill Received Talicia® Licensing Payments Totaling $1.1 Million
#Customers #FDA approved/pending approval
Aug 18, 2025
www.prnewswire.com
RedHill has received its first Talicia sales milestone payment as well as royalties and other payments, totaling $1.1 million, following the first ex-U.S....
#Customers #FDA approved #Partners
Jul 21, 2025
www.prnewswire.com
The positive FDA feedback allows for: A novel Phase 2 RHB-204[1] study, planned to be the first ever clinical study in a specifically defined Mycobacterium...
#Product Stage #Partners
Jul 21, 2025
finance.yahoo.com
RedHill Receives Positive FDA Feedback on Pathway to Approval of Groundbreaking RHB-204 for Crohn's Disease
#Product Stage #Partners
Jul 1, 2025
finance.yahoo.com
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
undefined
Jul 1, 2025
finance.yahoo.com
RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer
#Product Stage
Jul 1, 2025
www.prnewswire.com
Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer...
#Product Stage #Partners
May 13, 2025
finance.yahoo.com
RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win
#Product Stage #Partners
May 2, 2025
finance.yahoo.com
RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress
undefined
Apr 28, 2025
finance.yahoo.com
RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107
#Product Stage #FDA approved/pending approval
Apr 28, 2025
www.prnewswire.com
Strong Use of Composition-of-Matter Coverage: Patent protects the molecular structure of RHB-107, providing market exclusivity beyond method-of-use claims...
#Product Stage #FDA approved/pending approval
Apr 17, 2025
finance.yahoo.com
RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency
#Public Trading
Apr 16, 2025
finance.yahoo.com
RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption
#Product Stage #FDA approved/pending approval
Apr 10, 2025
finance.yahoo.com
RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights
#Product Stage #Partners #Customers #Investment
Mar 31, 2025
uk.finance.yahoo.com
Surrey loses rush-hour taxis to thousands of school runs
#Customers #Partners
Mar 18, 2025
finance.yahoo.com
RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation
#Product Stage #Partners
Mar 18, 2025
www.prnewswire.com
RedHill plans to submit UK MAA1 for Talicia for H. pylori infection, using MHRA's2 new fast-track approval process, referencing FDA approval, with potential UK...
undefined
Mar 12, 2025
www.prnewswire.com
The planned innovative Phase 2 study of RHB-2041 will be the first ever clinical study in Crohn's Disease (CD) patients who are all MAP-positive, and will...
undefined
Mar 12, 2025
finance.yahoo.com
RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results
#Product Stage
Feb 27, 2025
www.prnewswire.com
Guy Goldberg, RedHill's Chief Business Officer, presents today a business update at the European Life Sciences CEO Forum The update covers: The recent...
#Product Stage #Partners #Customers #FDA approved/pending approval
Feb 27, 2025
finance.yahoo.com
RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum
#Product Stage #Partners #Customers
Feb 26, 2025
www.pharmaceutical-technology.com
RedHill and Hyloris sign agreement for Bekinda’s development
#Partners #Product Stage
Feb 25, 2025
www.prnewswire.com
- Hyloris will pay RedHill an upfront payment and up to $60 million in potential milestone payments, plus up to mid-20s percent royalties on revenues, in...
#Partners
Feb 25, 2025
finance.yahoo.com
RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties
#Partners
Feb 5, 2025
www.clinicaltrialsarena.com
RedHill Biopharma launches trial of combination therapy for prostate cancer
#Product Stage
Feb 4, 2025
finance.yahoo.com
RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer
#Product Stage #Partners
Feb 4, 2025
www.prnewswire.com
The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with...
#Product Stage #Partners #Investment
Feb 4, 2025
www.prnewswire.com
The 80-patient placebo-controlled randomized Phase 2 study will evaluate the efficacy of opaganib in combination with Bayer's darolutamide in men with...
#Product Stage #Partners #Investment
Jan 21, 2025
finance.yahoo.com
RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published
#Customers
Dec 10, 2024
finance.yahoo.com
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
#Partners
Dec 3, 2024
finance.yahoo.com
RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court
#Partners
Dec 2, 2024
finance.yahoo.com
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
undefined
Dec 2, 2024
www.prnewswire.com
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the Company has...
undefined
Oct 28, 2024
finance.yahoo.com
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
undefined
Oct 23, 2024
finance.yahoo.com
RedHill Biopharma and Duke Collaborate on Opaganib Development
#Partners
Oct 22, 2024
www.prnewswire.com
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
#Partners
Oct 14, 2024
www.prnewswire.com
RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment
#Partners
Oct 1, 2024
www.prnewswire.com
RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians
#Customers #Partners
Oct 1, 2024
finance.yahoo.com
RedHill Biopharma Secures Opaganib COVID-19 Patent
undefined
Sep 30, 2024
www.prnewswire.com
RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041
#Customers #Partners
Sep 9, 2024
www.prnewswire.com
RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines
#Customers
Sep 5, 2024
www.prnewswire.com
/PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it received...
#Public Trading
Sep 5, 2024
www.prnewswire.com
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
#Public Trading
Sep 3, 2024
www.prnewswire.com
New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality
#Customers #Partners
Aug 29, 2024
www.prnewswire.com
RedHill Biopharma Announces First Half 2024 Business Highlights
#Customers #Partners #Investment #Layoffs
Aug 29, 2024
www.prnewswire.com
A transformed RedHill: Numerous potential catalysts Strengthened cash balance and control over our destiny following the Termination Agreement with Movantik...
#Customers #Partners #Investment #Layoffs
Aug 26, 2024
www.prnewswire.com
RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma
#Customers #Partners
Aug 21, 2024
www.prnewswire.com
Talicia® Launched in the United Arab Emirates
#Customers #Expand
Aug 21, 2024
finance.yahoo.com
Three Undiscovered Gems in the United States Market
#Investment, Public Trading
Aug 19, 2024
finance.yahoo.com
Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested
#Public Trading
Aug 19, 2024
www.prnewswire.com
RedHill Announces Positive Obesity and Diabetes Results with Opaganib
#Investment #Partners
Aug 16, 2024
www.prnewswire.com
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
#Public Trading #Management Changes
Aug 1, 2024
www.prnewswire.com
Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease
#Investment, Expand
Jul 22, 2024
www.prnewswire.com
RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien
#Partners
Jul 9, 2024
www.prnewswire.com
RedHill Biopharma Terminates License Agreement for Aemcolo®
#Partners
Jun 3, 2024
www.prnewswire.com
RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
#Investment
May 22, 2024
uk.finance.yahoo.com
Pensioners win £9,000 back in 16-year council tax battle
#Customers
May 6, 2024
www.prnewswire.com
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
#Investment
Apr 24, 2024
www.prnewswire.com
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
#Investment #Partners
Apr 10, 2024
finance.yahoo.com
RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)
#Public Trading
Apr 8, 2024
www.prnewswire.com
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
#Investment #Expand
Apr 2, 2024
www.prnewswire.com
RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
#Investment
Mar 11, 2024
www.prnewswire.com
RedHill Announces New USPTO Patent Covering Talicia® Through 2034
#Investment
Mar 5, 2024
www.prnewswire.com
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
#Partners
Feb 20, 2024
www.prnewswire.com
RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
#Investment #Partners
Jan 26, 2024
www.prnewswire.com
RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
#Investment
Jan 25, 2024
www.prnewswire.com
RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
#Customers
Jan 25, 2024
www.prnewswire.com
RedHill Biopharma Announces $8 Million Registered Direct Offering
#Investment
Dec 20, 2023
www.prnewswire.com
RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
#Investment
Dec 12, 2023
www.prnewswire.com
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
#Public Trading
Dec 4, 2023
www.prnewswire.com
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
#Investment
Dec 4, 2023
www.prnewswire.com
RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
#Investment
Nov 27, 2023
www.prnewswire.com
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
#Investment
Nov 14, 2023
www.prnewswire.com
RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market
#Public Trading
Oct 3, 2023
www.prnewswire.com
RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study
#Investment
Sep 22, 2023
www.prnewswire.com
RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
#Public Trading
Sep 18, 2023
www.prnewswire.com
RedHill Announces FDA sNDA Approval for Talicia®
#Customers #Partners
Sep 5, 2023
www.prnewswire.com
RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)
#Investment
Aug 17, 2023
www.prnewswire.com
RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
#Investment #Management Changes
Aug 1, 2023
www.prnewswire.com
RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.
#Partners #Expand
Jul 31, 2023
www.prnewswire.com
RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
#Investment #Partners
Jul 25, 2023
www.prnewswire.com
RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise
#Investment
Jul 21, 2023
www.prnewswire.com
RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development
#Investment #Partners
Jul 21, 2023
www.prnewswire.com
RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds
#Investment
Jun 12, 2023
www.prnewswire.com
RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights
#Investment #Management Changes
May 22, 2023
www.prnewswire.com
RedHill Provides R&D Update
#Management Changes
May 15, 2023
www.prnewswire.com
RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
#Public Trading
May 9, 2023
www.prnewswire.com
RedHill Publishes New Talicia® Data on Generic Non-Bioequivalence in AP&T and Presents New Dosing Data at Digestive Disease Week
#Customers
May 1, 2023
www.prnewswire.com
RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting
#Partners
Apr 28, 2023
www.prnewswire.com
RedHill Biopharma Announces Q4/22 & Full-Year 2022 Results and Operational Highlights
#Investment, Expand
Apr 17, 2023
finance.yahoo.com
Benign Growth For RedHill Biopharma Ltd. (NASDAQ:RDHL) Underpins Stock's 41% Plummet
#Customers
Apr 11, 2023
www.prnewswire.com
RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
#Public Trading
Apr 3, 2023
www.prnewswire.com
RedHill Biopharma Announces Closing of $6 Million Registered Direct Offering
#Investment
Mar 30, 2023
www.prnewswire.com
RedHill Biopharma Announces $6 Million Registered Direct Offering
#Investment
Mar 23, 2023
finance.yahoo.com
RedHill Biopharma Ltd.'s (NASDAQ:RDHL) market cap dropped US$146m last week; Individual investors bore the brunt
#Customers #Investment
Mar 21, 2023
www.prnewswire.com
RedHill Initiates First Community-Setting Warranty Program to Refund Talicia Non-Responders
#Customers
Mar 16, 2023
www.prnewswire.com
RedHill Biopharma Announces Plan to Implement ADS Ratio Change
#Public Trading #Management Changes
Mar 9, 2023
www.prnewswire.com
RedHill Biopharma Announces Definitive Agreement for Up To $6 Million Private Placement with a Single Investor
#Investment
Feb 28, 2023
finance.yahoo.com
RedHill Biopharma Ltd Announces RDHL Opaganib Selected by NIH RNCP For Development
#Partners
Feb 28, 2023
www.prnewswire.com
RedHill's Opaganib Selected by the NIH Radiation and Nuclear Countermeasures Program
#Partners
Feb 16, 2023
finance.yahoo.com
RedHill Biopharma Ltd Announces RedHill's RHB-102 Positive MHRA Meeting & MAA Plan
#Investment #Expand
Feb 16, 2023
www.prnewswire.com
RedHill Announces Positive MHRA Meeting and Planned UK Marketing Authorisation Application of RHB-102 (BEKINDA®) for Oncology Support
#Customers #Expand
Feb 15, 2023
www.prnewswire.com
RedHill Biopharma Announces Positive FDA Meeting Regarding Opaganib for Acute Nuclear Radiation Syndrome
#Partners
Feb 10, 2023
finance.yahoo.com
Raleigh pharma sheds debt in exchange for top-selling drug. Now what?
null
Oct 26, 2022
www.prnewswire.com
RedHill Presents New Talicia® and Movantik® Data Analyses at ACG 2022
#Customers, Investment
May 9, 2022
www.prnewswire.com
RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare Investor
#Investment
Apr 11, 2022
www.benzinga.com
RedHill Biopharma Says Opaganib Can Potentially Work Against COVID-19 Omicron Subvariants - Redhill Biopharma (NASDAQ:RDHL)
#Customers
Mar 1, 2022
www.eurekalert.org
RedHill announces positive phase 2 study results with oral RHB-107 in non-hospitalized COVID-19
#Investment
Jan 6, 2022
www.prnewswire.com
RedHill Biopharma and Gaelan Medical Enter Into License Agreement for Talicia® for the United Arab Emirates
#Partners #Investment
Nov 18, 2021
www.prnewswire.com
RedHill Biopharma Announces Underwritten Public Offering of American Depositary Shares
#Public Trading #Investment
Sep 14, 2021
www.prnewswire.com
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients
#Customers
Feb 28, 2021
www.calcalistech.com
Israel's RedHill Biopharma testing oral pill that cures Covid-19 symptoms
#Customers, Public Trading
Dec 15, 2020
www.prnewswire.com
RedHill's Phase 2/3 COVID-19 Candidate Opaganib Reduces ARDS-Related Blood Clotting in Preclinical Model
#Investment #Expand
Dec 2, 2020
www.usnews.com
Coronavirus Pandemic Boosting Anti-Virus Research Around the World
null
Nov 26, 2020
www.pharmanewsdaily.com
RedHill Biopharma expands manufacturing capacity of Covid-19 drug candidate opaganib in US - www.PharmaNewsDaily.com
#Partners #Expand
Oct 14, 2020
www.calcalistech.com
Israel's Redhill Biopharma signs manufacturing deal for potential Covid-19 treatment
#Partners #Expand
Oct 14, 2020
www.globenewswire.com
RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections
#Investment #Expand
Oct 8, 2020
www.globenewswire.com
RedHill Biopharma Adds Israel Rights to Movantik® From AstraZeneca
#Partners #Expand
Oct 7, 2020
www.globenewswire.com
RedHill Biopharma's Opaganib COVID-19 Study Passes Second Independent Committee Review
#Investment
Sep 22, 2020
www.globenewswire.com
Brazil Approves RedHill Biopharma's Phase 2/3 COVID-19 Study with Opaganib
#Investment, Expand
Sep 8, 2020
www.globenewswire.com
RedHill Biopharma's Opaganib Demonstrates Complete Inhibition of SARS-CoV-2
#Investment #Expand
Sep 3, 2020
www.globenewswire.com
RedHill Biopharma's Opaganib Awarded COVID-19 Grant by State of Pennsylvania
#Investment #Partners #Expand
Aug 27, 2020
www.globenewswire.com
RedHill Biopharma Announces Positive Recommendation from Independent Committee to Continue U.S. Phase 2 COVID-19 Study, and Approval of COVID-19 Phase 2/3 Study in Italy
#Investment, Expand
Aug 13, 2020
www.globenewswire.com
RedHill Biopharma and Cosmo Pharmaceuticals to Expand Strategic Partnership with Exclusive Licensing Agreement and Manufacturing Agreement for Multiple Products
#Partners #Investment
Aug 11, 2020
www.globenewswire.com
RedHill Biopharma's Phase 2/3 COVID-19 Study Approved in Mexico
#Investment, Expand
Aug 3, 2020
www.globenewswire.com
RedHill Biopharma Announces New Agreement with Daiichi Sankyo for Movantik®
#Acquisition #Partners
Jul 31, 2020
www.globenewswire.com
RedHill Biopharma Announces FDA Clearance for Pivotal Phase 3 Study with RHB-204 for NTM Infections
#Investment
Jul 30, 2020
www.globenewswire.com
RedHill Biopharma Initiates Global Phase 2/3 Study for COVID-19
#Investment, Expand
Jul 28, 2020
www.globenewswire.com
RedHill Biopharma Publishes Positive IBS-D Phase 2 Study Data in The American Journal of Gastroenterology
#Investment #Expand
Jul 22, 2020
www.globenewswire.com
RedHill Biopharma Accelerates Phase 2/3 COVID-19 Program with Addition of Brazil and Mexico
#Customers, Expand
Jul 16, 2020
www.globenewswire.com
RedHill Biopharma Receives Approval for Phase 2/3 COVID-19 Study in Russia
#Investment #Expand
Jun 29, 2020
www.globenewswire.com
RedHill Biopharma Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in the UK
#Customers #Expand
Jun 24, 2020
www.globenewswire.com
Publication of Data from Severe COVID-19 Patients Shows Substantial Benefit to Patients Treated with RedHill's Opaganib Compared to Matched Case-Control Group
#Investment #Expand
Jun 18, 2020
www.globenewswire.com
RedHill Biopharma Expands Opaganib COVID-19 Phase 2/3 Study with Clinical Trial Applications in Italy and UK
#Investment, Customers
Jun 10, 2020
www.globenewswire.com
RedHill Biopharma Submits COVID-19 Clinical Trial Application for Phase 2/3 Study with Opaganib
#Investment #Expand
Jun 8, 2020
www.globenewswire.com
RedHill Biopharma to Provide Update on its COVID-19 and other Development Programs at MedInvest Virtual Infectious Diseases and Immunology Conference
#Management Changes
May 8, 2020
www.globenewswire.com
RedHill Biopharma Receives FDA Approval for COVID-19 Clinical Study with Opaganib in the U.S.
#Investment #Expand
May 5, 2020
www.globenewswire.com
RedHill Biopharma Announces Publication of Talicia® Pivotal Phase 3 Study Results in Annals of Internal Medicine
#Customers, Expand
Apr 20, 2020
www.globenewswire.com
RedHill Biopharma Announces Agreement with NIAID to Evaluate RHB-107 Against COVID-19
#Partners
Apr 13, 2020
www.globenewswire.com
RedHill Biopharma Provides Initial Update from its Opaganib COVID-19 Compassionate Use Program in Israel
#Customers #Partners #Expand
Apr 7, 2020
www.timesofisrael.com
Israel's Redhill Biopharma gets green light for experimental COVID-19 treatment
null
Mar 15, 2020
www.israel21c.org
Israeli pharma company launches drug for H. pylori in US market
#Customers #Expand
Mar 11, 2020
www.globenewswire.com
RedHill Biopharma Provides Update on Opaganib (Yeliva®)
#Investment #Expand
Feb 25, 2020
www.globenewswire.com
RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners
#Investment #Acquisition #Partners
Feb 25, 2020
en.globes.co.il
RedHill buys AstraZeneca constipation drug rights
#Acquisition #Investment
Jan 27, 2020
www.globenewswire.com
RedHill Biopharma Launches H. pylori Disease State Awareness Field Campaign Ahead of Talicia® Launch
#Customers #Expand
Jan 21, 2020
www.globenewswire.com
RedHill Biopharma to Focus Commercial Efforts on Talicia® and Aemcolo®;Discontinuing Promotion of Legacy Products
#Partners
Jan 2, 2020
www.globenewswire.com
RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106
#Partners
Dec 17, 2019
www.globenewswire.com
RedHill Biopharma Initiates U.S. Promotion of Aemcolo® for Travelers' Diarrhea
#Customers #Partners #Investment #Expand
Nov 15, 2019
www.globenewswire.com
Dual-Listed RedHill Biopharma to Voluntarily Delist from Tel-Aviv Stock Exchange
#Public Trading
Nov 12, 2019
www.globenewswire.com
RedHill Biopharma Announces Publication of RHB-102 Gastroenteritis Phase 3 Study Results in JAMA
#Investment #Expand
Nov 5, 2019
www.calcalistech.com
RedHill Receives FDA Approval for H. Pylori Gastric Drug
null
Oct 18, 2019
www.globenewswire.com
RedHill Biopharma Announces $36 Million Strategic Investment by Cosmo Pharmaceuticals and U.S. Rights to Approved Travelers' Diarrhea Drug AEMCOLO
#Investment #Partners
Oct 11, 2019
www.globenewswire.com
RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn's Disease
#Investment
Aug 21, 2019
www.globenewswire.com
RedHill Biopharma Announces Acceptance of Oral Presentations on RHB-105 (H. pylori) and RHB-104 (Crohn's Disease) Phase 3 Data at ACG 2019 Annual Scientific Meeting
#Investment #Expand
Jul 3, 2019
www.globenewswire.com
RedHill Biopharma Announces FDA Acceptance of New Drug Application for Talicia®
#Investment #Customers
Jun 10, 2019
www.globenewswire.com
RedHill Biopharma Receives Allowance for New U.S. Patent Covering RHB-104 for Crohn's Disease and RHB-204 for NTM Infections
#Investment, Expand
May 28, 2019
www.globenewswire.com
RedHill Biopharma Appoints Dr. June Almenoff as Chief Scientific Officer
#Management Changes #Expand
May 21, 2019
www.globenewswire.com
RedHill Biopharma Expands Commercial Management Team Ahead of Planned Talicia® Launch
#Management Changes #Expand
May 7, 2019
www.globenewswire.com
RedHill Biopharma Submits New Drug Application for Talicia® for H. pylori Infection
#Investment #Expand
Mar 4, 2019
www.globenewswire.com
RedHill Biopharma Announces New European and Japanese Patents for Talicia®
#Investment
Jan 17, 2019
globenewswire.com
RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA® for H. pylori Infection
#Investment
Dec 9, 2018
en.globes.co.il
RedHill Biopharma raises $20m on Nasdaq
#Investment
Dec 3, 2018
www.timesofisrael.com
Israel's RedHill says drug shown effective in eradicating gut infection
null
Jul 30, 2018
www.timesofisrael.com
RedHill's drug for Crohn's disease shows positive results - study
null
Jul 24, 2018
www.calcalistech.com
Gastro Treatment Company RedHill Wants to Raise $117 on Nasdaq
#Investment #Public Trading
Nov 17, 2017
seekingalpha.com
RedHill Biopharma: When Good News Means Nothing (NASDAQ:RDHL)
#Management Changes #Layoffs
Nov 13, 2017
globenewswire.com
RedHill Biopharma Announces Closing of Public Offering of its American Depositary Shares
#Investment #Public Trading
Apr 10, 2017
www.marketwired.com
http://www.marketwired.com/press-release/intelgenx-redhill-biopharma-announce-marketing-approval-rizaportr-migraines-luxembourg-otcqx-igxt-2209596.htm
#N/A
Dec 22, 2016
www.globes.co.il
RedHill BioPharma raises $38m in Nasdaq offering
#Investment #Public Trading
Jul 22, 2016
globenewswire.com
RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead of Confirmatory Phase III Study for H. pylori Infection
#N/A
Jul 19, 2015
www.globes.co.il
RedHill BioPharma raises $40 million on Nasdaq
#Investment #Public Trading
Jun 15, 2015
www.globes.co.il
RedHill Biopharma soars on Phase III trial results
#Investment
Feb 11, 2015
www.globes.co.il
RedHill Biopharma raises $12.5m on Nasdaq
#Investment
Dec 18, 2014
www.globes.co.il
RedHill boosted by University of Minnesota deal
#Acquisition #Partners
Jan 22, 2014
www.globes.co.il
RedHill Biopharma raises $11.7m in private placement
#Investment
Related Content
RedHill Biopharma Team
No Data, yet.
Sorry, no content found under this section.
Employees Over Time
Similar Companies
Driven by Finder AI
RedHill Biopharma Internal
Create note
Notes
(undefined)
Filter notes
Content Writer
undefined
BI Verification
undefined
Phone Number
undefined
Israel Register ID
undefined
Confidence Score
undefined
Missing Fields
undefined
Profile Creator
undefined
Profile Update
undefined
undefined
Access Comprehensive Financial Analytics
Create a free account to:
- Explore detailed financial analytics.
- Track company growth and size.
- Connect with company team members.
I already have access,
I already have access,